Paper Review Records
全部论文审稿周期
12 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
314
天
Illuminating the future: energy-based focal therapies for prostate cancer
作者
Anirban Goutam Mukherjee; Abilash Valsala Gopalakrishnan展开收起
作者单位
1. Department of Biotechnology, School of Sciences and Humanities, SR University, Warangal, India; 2. Department of Biomedical Sciences, School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, India展开收起
46
天
Robotic-assisted versus open radical nephrectomy with inferior vena cava thrombectomy for renal cell carcinoma: a systematic review and meta-analysis of perioperative outcomes and oncological endpoints
作者
Diego Villalobos-Almanza; Alfredo Salazar-Monroy; Daniel Olvera‐Posada展开收起
作者单位
1. Hospital Zambrano Hellion展开收起
66
天
MiR-590 suppresses the progression of non-small cell lung cancer by regulating YAP1 and Wnt/β-catenin signaling
作者
X. Hao; A. Su展开收起
作者单位
1. Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China; 2. General Department, Bejing Chaoyang District Sanhuan Cancer Hospital, Beijing, China展开收起
70
天
Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3
作者
X. Xie; J. Ji; X. Chen; W. Xu; H. Chen; S. Zhu; J. Wu; Y. Wu; Y. Sun; W. Sai; Z. Liu; M. Xiao; B. Bao展开收起
作者单位
1. Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, China; 2. Office of Infection Management, Affiliated Hospital of Nantong University, Nantong, China; 3. Department of Gastroenterology, Second People’s Hospital of Nantong, Nantong, China; 4. Medical School of Nantong University Oral Medicine, Nantong, China; 5. Blood Center of Jiangsu Province, Nanjing, China; 6. Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China展开收起
46
天
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
作者
P. García-Alfonso; M. Saiz-Rodríguez; R. Mondéjar; J. Salazar; D. Páez; A. M. Borobia; M. J. Safont; I. García-García; R. Colomer; X. García-González; M. J. Herrero; L. A. López-Fernández; F. Abad-Santos展开收起
作者单位
1. Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Sociedad Española de Oncología Médica (SEOM), Madrid, Spain; 2. Research Unit, Fundación Burgos por la Investigación de la Salud (FBIS), Hospital Universitario de Burgos, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Burgos, Spain; 3. Medical Oncology Service, Hospital Universitario de la Princesa, Sociedad Española de Oncología Médica (SEOM), Madrid, Spain; 4. Research Institute of Hospital de la Santa Creu I Sant Pau, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Barcelona, Spain; 5. Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, Sociedad Española de Oncología Médica (SEOM), Barcelona, España; 6. Clinical Pharmacology Service, Hospital Universitario La Paz, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Madrid, Spain; 7. Medical Oncology Service, Consorcio Hospital General Universitario de Valencia, Universidad de Valencia, CIBERONC, Sociedad Española de Oncología Médica (SEOM), Valencia, Spain; 8. Medical Oncology Service, Hospital Universitario de La Princesa y Cátedra de Medicina Personalizada de Precisión de la Universidad Autónoma de Madrid (UAM), Sociedad Española de Oncología Médica (SEOM), Madrid, Spain; 9. Hospital Pharmacy Service, Hospital General Universitario Gregorio Marañón, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Madrid, Spain; 10. Pharmacogenetics Platform, IIS La Fe-Hospital La Fe and Pharmacology Department, Universidad de Valencia, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Valencia, Spain; 11. Clinical Pharmacology Service, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Madrid, Spain展开收起
56
天
Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer
作者
H. Kim; Y. J. Heo; Y. A. Cho; S. Y. Kang; S. Ahn; K. -M. Kim展开收起
作者单位
1. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 2. The Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 3. Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea展开收起
FAQ
Clinical & Translational Oncology审稿要多久?
截至2026-11-19,CrushSCI 收录了 Clinical & Translational Oncology 的 12 篇完整审稿记录。最快一篇从收稿到录用用了 16 天(Future care for long-term cancer survivors: towards a new model,2021-07-26 收稿,2021-08-11 录用),最慢一篇用了 314 天;平均 78.2 天,中位数 55 天。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
